Skip to content

Gabapentin for the treatment of visual hallucination associated with Parkinson's disease

Gabapentin for the treatment of visual hallucination associated with Parkinson's disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181220008
Enrollment
Unknown
Registered
2018-12-20
Start date
2019-01-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

&#45
The patients was randomized to gabapentin for 4 weeks &#45
The dose of gabapentin depend on body weight&#44
if BW less than 50 kg titrate dose up to 300 mg/day&#44
if BW equal or more than 50 mg titrate dose up to 600 mg/day,The patients was randomized to quetiapine for 4 weeks &#45
The dose of quetiapine depend on body weight&#44
if BW less than 50 kg titrate dose up to 50 mg/day&#44
if BW equal or more than 50 mg titrate dose up to 75 mg/day
Active Comparator Drug,Active Comparator Drug
Gabapentin,Quetiapine

Sponsors

Research and Development Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: PD patients who are being the visual hallucination for at least 1 months duration.

Exclusion criteria

Exclusion criteria: 1. Pateints with communication problem 2. Patients who are taking gabapentin or antipsychotic medications

Design outcomes

Primary

MeasureTime frame
visual hallucination 4 weeks after take each medication interview

Secondary

MeasureTime frame
N/A N/A N/A

Countries

Thailand

Contacts

Public ContactChumpol Anamnart

Prapokklao Hospital

tom_ppk@yahoo.com0814306100

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026